

**Table 2.73. Cohort studies on smoking and endometrial cancer**

Reference Country and years of study	Study subjects	Cases	Exposure estimates	Relative risk (95%CI)	Comments
Loerbroks <i>et al.</i> (2007) 1986-1997	Netherlands Cohort Study, 62573 women	280 cases	Former Current <i>Duration (years)</i> 0.1-19 20-39 40+	0.83 (0.58–1.20) 0.59 (0.40–0.88) 0.77 (0.43–1.39) 0.89 (0.51–1.56) 0.37 (0.15–0.90)	Adjusted for age, BMI, parity, use of oral contraceptives, non-occupational physical activity, hypertension, age at first child birth, age at menopause, alcohol consumption; smoking duration was adjusted for current smoking status and number of cigarettes per day.
Viswanathan <i>et al.</i> (2005) 1976-2000	Nurses' Health Study, 96704 women	702 cases	Former Current <i>Pack years</i> 1-10 >10-20 >20-30 >30-40 >40-50 >50	0.83 (0.58–1.20) 0.59 (0.40–0.88) 0.82 (0.66–1.01) 0.59 (0.44–0.80) 0.87 (0.66–1.15) 0.84 (0.63–1.13) 0.57 (0.38–0.86) 0.50 (0.34–0.74)	Adjusted for BMI, parity, use of oral contraceptives, post-menopausal hormone use, hypertension, diabetes, age at menarche.
Furberg & Thune (2003) 1974-1981	A cohort of 24460 women in Norway	130 cases	Daily smoking (yes vs. no)	0.78 (0.53–1.14)	Adjusted for age
Folsom <i>et al.</i> (2003) 1986-2000	23335 post-menopausal women in the Iowa Women's Health Study, with 15 years of follow-up.	415 cases	Former Current	0.84 (0.64–1.08) 0.53 (0.37–0.75)	Adjusted for age
Bjørge <i>et al.</i> (2007) 1963-2001	1038018 women aged 20-74 years at baseline in the Million Women Norwegian Cohort	9227 cases (7164 endometrioid and 992 serous and clear cell)	<i>Endometrioid Adenocarcionomas</i> Former Current <i>Serous and Clear Cell Adenocarcionomas</i> Former Current	1.14 (0.77-1.68) 0.54 (0.35-0.83) 1.05 (0.73-1.51) 0.67 (0.47-0.97)	Adjusted for age, BMI, height

**Table 2.73. Cohort studies on smoking and endometrial cancer**

Reference Country and years of study	Study subjects	Cases	Exposure estimates	Relative risk (95%CI)	Comments
Lacey <i>et al.</i> (2007) 1995-2000	73211 women, aged 50-71 years, in the National Institutes of Health-AARP Diet and Health Study	433 cases	Former Current	0.81 (0.66-0.99) 0.66 (0.46-0.94)	Adjusted for age, oral contraceptive use, BMI, race, and menopausal status
Al-Zoughool <i>et al.</i> (2007) Europe 1992-2002	249986 women in the EPIC study with approximately 10 years of follow-up.	619 cases (126 pre-menopausal and 493 postmenopausal)	<b>Premenopausal</b> Former Current <i>Current cigarettes/day</i> 1-15 >15 <b>Postmenopausal</b> Former Current <i>Current cigarettes/day</i> 1-15 >15	0.78 (0.46-2.78) 1.79 (1.15-2.78) 1.45 (0.81-2.62) 2.58 (1.48-4.50) 0.88 (0.70-1.11) 0.78 (0.59-1.03) 0.84 (0.60-1.19) 0.54 (0.34-0.87)	Adjusted for age, BMI, physical activity, oral contraceptives use, parity, education, and alcohol consumption
Setiawan <i>et al.</i> (2007) USA 1993-2001	46933 post-menopausal women of mixed ethnic background in Hawaii and Los Angeles, California, followed for 7.3 years	321 cases	Former Current	1.16 (0.91-1.47) 0.72 (0.48-1.08)	Adjusted for age, race/ethnicity, diabetes, hypertension, family history of endometrial cancer, hormone therapy use, oral contraceptive use, parity, age at menarche, age at natural menopause, BMI
Lindemann <i>et al.</i> (2008) Norway 1984-2002	36761 women in Norway, followed for 15.7 years	222 cases	Former Current	1.06 (0.71-1.61) 0.55 (0.35-0.86)	Adjusted for age, physical activity, hypertension, alcohol consumption during the past two weeks, BMI, diabetes
Beral <i>et al.</i> (2005) United Kingdom 1996-2001	716738 post-menopausal women in the Million Women Study with an average 3.4 years of follow-up	1320 cases	<i>Women who last used combined HRT</i> Former Current <i>Women who last used cyclic combined HRT</i> Former Current <i>Women who last used tibolone</i> Former Current	0.63 (0.48-0.83) 1.12 (0.59-2.14) 1.04 (0.88-1.22) 1.08 (0.68-1.72) 1.77 (1.39-2.26) 1.59 (0.73-3.49)	Adjusted for age, time since menopause, parity, oral contraceptive use, BMI, alcohol consumption, region of residence, and SES